Navigation Links
Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
Date:1/30/2013

ential advantage is that the immunological memory induced by AE37 means the immune system may continue to scan for and kill HER2 cancer cells long after AE37 treatment has been completed.

Herceptin is approved for metastatic and early stage breast cancer patients. Its 2010 annual sales were nearly $6B. Given that the initial target population for AE37 in early stage breast cancer patients is twice that of Herceptin, AE37 has the potential to achieve blockbuster status.

The potency of AE37 derives from a fragment of the HER2 protein combined with a proprietary modification developed at Antigen Express. While similar fragments of HER2 are also in clinical development for early stage breast cancer patients with low HER2 expression, they lack the potency of AE37. Further, their mechanism of action requires use to be limited to a sub-group of people with a specific genetic immune type. The clinical use of these alternative HER2 immune fragments therefore must exclude roughly half of the women with early breast who would otherwise be eligible. No genetic immune limitation or exclusion from clinical use is required for AE37 treatment. Any market competition in early breast cancer from these alternate HER2 fragments would be limited to the genetic immune sub-group, with AE37 facing no competition in patients excluded from other treatments. Further, additional genetic immune profile testing adds another diagnostic step before a woman with early breast cancer could get a potential new treatment. Any agents requiring additional testing may be at a competitive disadvantage.

Another advantage that sets AE37 apart from other types of related vaccines is that it contains a proprietary modification that is exclusive to Antigen Express. The modification, termed Ii-Key, derives its name from the immune regulatory molecule from which it is derived (Ii protein) and the fact that it functions as a 'key' to deliver its payload (HER2 fragment) to critical components
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
10. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 2012  Biomerix Corporation announced today that it has received ... tissue repair mesh, a novel composite mesh intended for ... for the temporary bridging of fascial defects.  This approval ... certification in many other parts of the world that ...
... 2012  Sanofi US today announced that the U. S. ... injunction against a Synvisc-One ® (hylan ... ruling allows for a restricted launch of Seikagaku,s product ... prohibits Seikagaku from selling their product below the current ...
Cached Medicine Technology:Biomerix Receives CE Mark Approval For ASSURE Soft Tissue Repair Mesh 2Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product 2
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin ... the first provider of Exilis non-surgical fat reduction in New York. Due to ... a large International clientele. Many patients travel to New York to get their ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based ... its new True North Conference Center. The medical community, social workers, law enforcement, ... may be more aligned in the effort to better understand and combat sex ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Radiation Oncology (ASTRO) has released evidence-based guidelines to ... finding that hypofractionated (HF) WBI is effective for ... are published in the International Journal of ... , Studies have shown that WBI following breast ...
... that controls the number of hematopoietic stem cells cells ... In a report in the online Early Edition of ... from Massachusetts General Hospital (MGH) and the Harvard Stem Cell ... of these blood stem cells, an advance that may improve ...
... By Jenifer Goodwin HealthDay Reporter , ... outbreak of whooping cough in decades, public health officials ... those who come into contact with infants, to make ... With the incidence of whooping cough also higher than ...
... DC Delivering timely, open, online access to the ... will significantly increase the return on the public,s investment ... Houghton at the Centre for Strategic Economic Studies at ... on Investment in Open Archiving Publicly Funded Research Outputs," ...
... Yeni H. Ycel, an ophthalmic pathologist at St. Michael,s Hospital, ... the New York Academy of Medicine. Dr. Ycel received ... the human eye that may lead to new treatments for ... assumption that the eye has no lymphatics, the channels responsible ...
... accurately detect and alleviate symptoms of delirium in persons ... the National Institute of Nursing Research. The project, ... seeks to improve nurses, assessment skills and reduce the ... Delirium and dementia have similar symptoms -- decline in ...
Cached Medicine News:Health News:ASTRO publishes whole breast irradiation guidelines 2Health News:MicroRNA molecule increases number of blood stem cells, may help improve cancer treatment 2Health News:Spread of Whooping Cough Raises Concern 2Health News:Spread of Whooping Cough Raises Concern 3Health News:New study examines the economic returns of public access policies 2Health News:Nurses will test method for determining if it's dementia or delirium 2
Reagent Basin, 60mL, 5/Box...
For use with 8 channel pipets....
96 channel Parallel dispenser using Positive Air Displacement Technology...
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
Medicine Products: